News Item

Orion Biotechnology to Attend the LSX Investival Showcase & Jefferies Healthcare Conference

Ottawa, Ontario, Canada, Nov. 10, 2022 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs), today announced that it will be participating in Europe’s biggest dedicated healthcare investment week.

On November 14th, Anatole Klepatsky (COO), Dr. Oliver Hartley (VP Drug Discovery), and Dr. Ian McGowan (CMO) will be in London to connect with investment partners at the LSX Investival Showcase.

The Orion team will remain in London to attend the Jefferies Healthcare Conference from November 15th–17th. During this time, they will be available for meetings with institutional investors and thought leaders in the biotechnology and pharmaceutical sectors.

To learn more about Orion’s approach to GPCR drug discovery, you can schedule a meeting through the conference partnering platforms. 

Share on Facebook
Tweet Me
Share on LinkedIn

contact us

Leave  us a message and we will try to respond by the next business day

ORION Logo Pantone(375x133)

Our Headquarters

343 Preston Street

11th floor,

Ottawa, ON K1S 1N4

CANADA

info@orionbiotechnology.com

+1 343.291.1032

This website uses cookies to ensure you get the best experience on our site.  By using this website, you agree to our use of cookies.

contact us

Leave  us a message and we will try to respond by the next business day

ORION Logo Pantone(375x133)

Our Headquarters

343 Preston Street

11th floor,

Ottawa, ON K1S 1N4

CANADA

info@orionbiotechnology.com

+1 343.291.1032